Stryker (NYSE:SYK) Posts Earnings Results, Beats Expectations By $0.07 EPS

Stryker (NYSE:SYK) announced its quarterly earnings data on Thursday. The medical technology company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07, FiscalAI reports. The business had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.01 earnings per share.

Here are the key takeaways from Stryker’s conference call:

• Stryker reported strong 2025 results with organic sales up ~10.3% for the year, Q4 organic growth of 11%, more than $25 billion in sales, adjusted EPS growth (~11.8% to $13.63), and 2026 guidance of 8–9.5% organic growth and EPS of $14.90–$15.10.
• Robotics are a major tailwind — the company now has >3,000 Mako systems with record installs and high utilization (over two?thirds of U.S. knees), plus initial cases on the new handheld Mako RPS, supporting future implant and capital revenue.
• Broad product momentum — MedSurg/Neurotechnology, Instruments (U.S. organic +19.1%), Endoscopy, and Medical each posted strong growth, aided by new launches (e.g., Triathlon Gold, 1788 platform) and favorable ASC/capital demand.
• Tariff headwinds remain material — Stryker expects approximately $400 million of full?year tariff impact in 2026 (including a ~$200 million incremental hit in H1), which will pressure margins despite ongoing mitigation efforts.
• Vascular dynamics are mixed — hemorrhagic products and Inari/peripheral vascular showed strong procedural growth, but ischemic business faced competitive pressure and Q4 stocking/disruption (expected to be minimal in Q1), creating near?term uncertainty.

Stryker Trading Down 1.0%

Shares of Stryker stock traded down $3.45 during trading on Thursday, hitting $354.39. The company’s stock had a trading volume of 2,223,477 shares, compared to its average volume of 1,921,645. The stock has a market cap of $135.52 billion, a price-to-earnings ratio of 46.57, a price-to-earnings-growth ratio of 2.27 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. Stryker has a 52 week low of $329.16 and a 52 week high of $404.87. The stock has a 50-day moving average price of $359.50 and a two-hundred day moving average price of $372.07.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. Stryker’s payout ratio is presently 46.25%.

Insider Transactions at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares in the company, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 522,118 shares of company stock worth $185,381,932. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Stryker

Several institutional investors have recently bought and sold shares of SYK. Schnieders Capital Management LLC. bought a new stake in Stryker in the 2nd quarter valued at $205,000. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. McCollum Christoferson Group LLC lifted its position in Stryker by 11.4% in the third quarter. McCollum Christoferson Group LLC now owns 780 shares of the medical technology company’s stock worth $288,000 after buying an additional 80 shares during the last quarter. Kestra Investment Management LLC boosted its stake in shares of Stryker by 116.4% during the 2nd quarter. Kestra Investment Management LLC now owns 712 shares of the medical technology company’s stock worth $282,000 after purchasing an additional 383 shares during the period. Finally, Two Sigma Securities LLC bought a new position in shares of Stryker during the second quarter valued at approximately $271,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat: Stryker reported adjusted Q4 EPS $4.47 and revenue $7.17B, topping consensus on both measures — a clear near?term positive for revenue and profitability trends. Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Raised profit outlook: Management raised its full?year profit forecast, citing strong implant and capital product demand — a catalyst for forward earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Solid full?year momentum and guidance: FY2025 adjusted EPS and margins expanded (adjusted EPS $13.63; adjusted operating margin +100 bps year) and management guided 2026 organic net?sales growth ~8.0%–9.5% with adjusted EPS $14.90–$15.10 — supports medium?term upside. Stryker reports 2025 operating results and 2026 outlook
• Neutral Sentiment: Analyst/street context: Several firms maintain positive ratings (e.g., Piper Sandler reaffirmed a Buy), and sell?side median targets remain well above the current price — supports sentiment but may already be priced in. Piper Sandler Remains a Buy on Stryker (SYK)
• Neutral Sentiment: Conference call / details ahead: Management held an earnings call and provided granular segment math and non?GAAP reconciliations — useful for modeling but unlikely to shift the stock absent new guidance tweaks. Press release & conference details
• Negative Sentiment: Mixed segment dynamics: MedSurg & Neuro showed double?digit growth, but spinal implants and some orthopaedics subcategories remain weak or volatile — a potential drag on sustained top?line upside. Stryker Reports Strong Q4 and Full-Year 2025 Results
• Negative Sentiment: One?offs and legacy charges: Prior goodwill impairments, tax adjustments and other special items still affect GAAP comparisons and introduce modeling uncertainty — some investors may be trimming positions until recurring earnings visibility is clearer. Full release: reconciliations and note on adjustments
• Negative Sentiment: Valuation and profit?taking risk: SYK trades at a premium P/E (~46 on reported metrics) and recent insider selling activity may encourage short?term profit?taking despite the beat. Analyst comparison & metrics

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SYK. Wells Fargo & Company boosted their price objective on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a report on Friday, November 14th. The Goldman Sachs Group set a $399.00 price target on Stryker in a research report on Friday, January 9th. UBS Group set a $408.00 price objective on Stryker in a report on Monday, October 13th. Barclays increased their target price on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Finally, Raymond James Financial raised Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a research note on Tuesday, January 6th. Twelve analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $425.94.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.